Skip to main content
. 2015 Feb 7;116:76–84. doi: 10.1016/j.antiviral.2015.01.011

Table 2.

Structure and antiviral activity of K11777 analogs modified at the P3 position.

Inline graphic
Compound P3 substituent
R=		 MW pKaa HIV-luc
(SARS-CoV S)b
IC50 (nM)		 HIV-luc
(EBOV GP)
IC50 (nM)
K11777 Me 575 7.02 0.32 ± 0.02 0.36 ± 0.02
SMDC-256122 Et 589 7.29 0.04 ± 0.01 0.12 ± 0.01
SMDC-256123 i-Pr 603 7.57 0.11 ± 0.01 0.25 ± 0.07
SMDC-256157 n-Pr 603 7.59 0.24 ± 0.03 0.42 ± 0.03
SMDC-256158 Ph 637 3.42 2.49 ± 0.34 2.69 ± 0.43
SMDC-256159 —CH2CH2OCH3 619 6.82 0.07 ± 0.02 0.16 ± 0.02
SMDC-256160 t-Bu 617 7.87 0.08 ± 0.01 0.11 ± 0.03
SMDC-256161 Cyclopentyl 629 8.01 0.25 ± 0.16 0.18 ± 0.01
SMDC-256162 Cyclopropylmethyl 615 7.73 0.16 ± 0.03 0.10 ± 0.01
a

Calculated in MarvinSketch 5.5.0.1 from ChemAxon Ltd.

b

IC50 (inhibitory concentration) values of SARS-CoV or EBOV are the concentrations required to inhibit the infectivity of SARS-CoV or EBOV pseudotyped viruses on 293T-ACE2 cells by 50%, which were determined from dose response curves. A non-linear regression analysis based on the Sigmoidal dose response equation was applied to the percent inhibition and concentration data. Data is shown as means of quadruplicate measurements ± standard deviation. Values are representative of at least three independent experiments.